Opdivo/Yervoy improves survival in pleural mesothelioma
Combination therapy showed benefit in hard-to-treat cancer type
Read MoreCombination therapy showed benefit in hard-to-treat cancer type
Read MoreNew government package will be worth £172m
Read MorePhase III study of drug in Crohn’s disease is ongoing
Read MoreAllergy drug approved for severe chronic rhinosinusitis with nasal polyps
Read MoreScientists from the University of Oxford say the drug is being ‘discarded prematurely’
Read More




PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
